Vaxcyte, Inc. — Director's Dealing 2020

Jun 12, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2020-06-11

Reporting Person: EMSTER KURT VON (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$0.00		Common Stock, $0.001 par value per share (2185415)		Indirect
Series B Preferred Stock	$0.00		Common Stock, $0.001 par value per share (1217074)		Indirect
Series C Preferred Stock	$0.00		Common Stock, $0.001 par value per share (454812)		Indirect
Series D Preferred Stock	$0.00		Common Stock, $0.001 par value per share (298917)		Indirect

Footnotes

F1: The shares are held by Abingworth Bioventures VI LP ("Abingworth VI"). Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI.

F2: From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the reporting person, Abingworth VI or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

F3: Each share of Series A, Series B, Series C and Series D Preferred Stock is convertible into one share of Common Stock, $0.001 par value per share ("Common Stock") on a 1:1 basis and has no expiration date. Immediately prior to the consummation of the Issuer's initial public offering, all shares of Series A, Series B, Series C and Series D Preferred Stock will be converted into shares of Common Stock for no consideration.